Symbol | Exchange | Currency |
|---|
(Adds index close) By Chijioke Ohuocha ABUJA, Nov 11 (Reuters) - Nigerian stocks climbed to a morethan two-year high on Wednesday as domestic funds bought sharesacross sectors and...
Jan 31 (Reuters) - Fidson Healthcare PLC FIDSON.LG :* QTRLY REVENUE 3.59 BILLION NAIRA VERSUS 4.78 BILLION NAIRA* QUARTERLY PRETAX PROFIT 57.5 MILLION NAIRA VERSUS LOSS...
Oct 29 (Reuters) - Fidson Healthcare PLC FIDSON.LG :* QTRLY LOSS BEFORE TAX 4.4 MILLION NAIRA VERSUS PROFIT OF332.4MILLION NAIRA* QTRLY REVENUE 3.10 BILLION NAIRA VERSUS 4.01...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Sell | Strong Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Neutral | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Neutral | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 23.70 | 23.80 | 23.25 | +0.45 | +1.94% | 32.03M | Lagos | |||
| 5.65 | 5.70 | 5.60 | -0.05 | -0.88% | 1.25M | Lagos | |||
| 0.20 | 0.00 | 0.00 | -0.01 | -4.76% | 1.42M | Lagos | |||
| 19.85 | 19.85 | 19.85 | +1.15 | +6.15% | 17.41K | Lagos | |||
| 75.90 | 75.90 | 75.90 | -3.00 | -3.80% | 16.46K | Lagos | |||
| 29.00 | 29.00 | 29.00 | -0.50 | -1.69% | 557.30K | Lagos | |||
| 8.45 | 8.55 | 8.40 | +0.05 | +0.60% | 28.76M | Lagos | |||
| 21.00 | 21.00 | 21.00 | 0.00 | 0.00% | 817.99K | Lagos | |||
| 5.30 | 5.30 | 5.30 | 0.00 | 0.00% | 1.26M | Lagos | |||
| 7.30 | 7.35 | 7.20 | 0.00 | 0.00% | 5.81M | Lagos | |||
| 30.00 | 30.00 | 29.50 | +0.45 | +1.52% | 11.19M | Lagos | |||
| 216.00 | 216.00 | 216.00 | +1.00 | +0.47% | 298.85K | Lagos | |||
| 45.40 | 46.00 | 46.00 | +0.90 | +2.00% | 757.38K | Lagos | |||
| 1.15 | 1.15 | 1.15 | +0.020 | +1.77% | 236.67K | Lagos | |||
| 0.34 | 0.00 | 0.00 | +0.03 | +9.68% | 2.14M | Lagos |
Fidson Healthcare Plc is a Nigeria-based pharmaceutical manufacturing company. The principal activities of the Company are the manufacture and distribution of pharmaceutical products. The Company's segments include over the counter, ethical product and consumer. The over the counter segment represents the products that may be sold directly to the consumer without a prescription. The ethical products segment represents the drugs, which would be sold to the consumer only on the possession of a valid prescription. The consumer segment represents household items. The Company offers various drug products and formulations across different therapeutic classes and pharmacological segments, which include antacid and ulcer care; anti-diabetic; anti-malaria; cardio-vascular; cough, cold, catarrh and allergies; multivitamin-hematinics; nuero-psychiatry/anti-physiotic; anti-diarrhea; osteo-care; pain-relievers, and thrombo-prophalyti.